NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer

NALIRIFOX Plus Targeted Therapy Versus FOLFOX Plus Targeted Therapy as First-line Treatment for Metastatic Colorectal Cancer is a phase 3, randomised interventional study registered as NCT07309289 by Shanghai Zhongshan Hospital, with a registry enrolment figure of 144 participants, started 2025-07-01 and due to reach its primary completion in 2029-03-01. Interventions recorded: NALIRIFOX plus targeted therapy; FOLFOX plus targeted therapy. Conditions listed: Metastatic Colorectal Cancer (CRC). Primary outcome: 18 month PFS rate. Colorectal eligibility wording from the registry: "* Histopathologically confirmed patient with an inoperable metastatic colorectal adenocarcinoma". Sites: China. No results are recorded here; the registry entry is the source.